(Q33794292)

English

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

multicenter clinical trial

0 references

plaque psoriasis

1 reference

based on heuristic

inferred from title

1

object named as

Torello Lotti

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Sergio Chimenti

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Andreas Katsambas

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jean-Paul Ortonne

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Louis Dubertret

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Daiana Licu

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jan Simon

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

1 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Archives of Drug Information

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

9-18

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855833

4 July 2018

Pathogenesis and clinical features of psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855833

4 July 2018

Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855833

4 July 2018

Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855833

4 July 2018

Psoriasis: epidemiology, clinical features, and quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855833

4 July 2018

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855833

4 July 2018

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855833

4 July 2018

Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855833

30 October 2018

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855833

30 October 2018

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855833

30 October 2018

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2855833

30 October 2018

The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/20428228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20428228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20428228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical benefits in patients with psoriasis after efalizumab therapy: clinical trials versus practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20428228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20428228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1753-5174.2009.00026.X

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33794292&oldid=1961018922"